FDA Accepts Supplemental NDA for ZORYVE (Roflumilast) by Arcutis
The FDA has accepted a supplemental NDA for ZORYVE, which contains the active ingredient roflumilast.
Therapeutic Area
Therapeutic area intelligence for Topical Anti-inflammatory with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.